Full text is available at the source.
Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting β/γ-Secretases Activity and Enhancing α-Secretases
Berberine reduces harmful protein buildup in a mouse Alzheimer's model by blocking harmful enzymes and boosting protective ones
AI simplified
Abstract
Berberine (BBR) decreased amyloid-beta levels in the hippocampus of APP/PS1 mice.
- BBR improved learning and memory deficits in a mouse model of Alzheimer's disease.
- The treatment significantly reduced levels of BACE1 and sAPP-β in the hippocampus.
- BBR decreased the expression of components associated with γ-secretase activity.
- Levels of sAPPα, ADAM10, and ADAM17 significantly increased in BBR-treated mice.
AI simplified